MSN

JUL 28, 2026 · REGULATORY APPROVAL

FDA approval: Sugammadex

U.S. Food and Drug Administration

FDA approval of sugammadex sodium for intravenous use; this is a regulatory action record that does not contain clinical trial outcome data.

JUL 20, 2026 · REGULATORY APPROVAL

FDA approval: Carfilzomib

U.S. Food and Drug Administration

FDA approval of a generic carfilzomib ANDA expanding access to this proteasome inhibitor formulation.

JUN 4, 2026 · REGULATORY APPROVAL

FDA approval: Cangrelor

U.S. Food and Drug Administration

FDA approval of cangrelor powder for intravenous use; this is a regulatory action record that does not contain clinical trial data or efficacy evidence.

APR 6, 2026 · REGULATORY APPROVAL

FDA approval: Dapagliflozin

U.S. Food and Drug Administration

FDA approval of a generic dapagliflozin formulation; regulatory action does not establish comparative efficacy or clinical superiority.

APR 6, 2026 · REGULATORY APPROVAL

FDA approval: Dapagliflozin AND Metformin Hydrochloride

U.S. Food and Drug Administration

FDA approval of a fixed-dose combination of dapagliflozin and metformin; this is a regulatory action, not a clinical evidence report, and does not contain trial outcomes or comparative efficacy data.